The Indian Pharmacopoeia Commission and the Uttar Pradesh Promote Pharma Council have signed a memorandum of understanding on medicine quality, regulatory awareness and patient safety.
The agreement was signed at the YEIDA MedTech Investors Meet and Site Visit 2026 in Greater Noida on 14 July. It brings the national standards and safety institution together with a state-level industry-promotion body.
The partnership covers quality standards and regulatory compliance in the pharmaceutical and medical-device industries. It also includes work on innovation and capacity building for organisations operating in those sectors.
Joint training programmes, workshops and awareness sessions are planned on the Indian Pharmacopoeia. That publication sets official quality specifications used for medicines in India and gives manufacturers and laboratories a common standards reference.
The organisations will also work on pharmacovigilance and materiovigilance. Pharmacovigilance concerns the detection and assessment of suspected adverse effects associated with medicines, while materiovigilance performs a related safety function for medical devices.
The release identifies digital reporting tools for micro, small and medium enterprises as another area of cooperation. Easier reporting can help smaller manufacturers and other participants submit adverse-event information through recognised systems instead of relying on informal communication.
Post-market surveillance is included because safety monitoring continues after a medicine or device reaches users. Reports from patients, professionals and manufacturers can reveal problems that were not apparent during earlier evaluation or production checks.
The MoU creates a framework for collaboration; it does not replace statutory approvals or exempt a company from regulatory duties. Its value will depend on the training delivered, use of the reporting tools and whether surveillance information leads to timely investigation and corrective action.
